BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 35272688)

  • 1. Subtypes in pancreatic ductal adenocarcinoma based on niche factor dependency show distinct drug treatment responses.
    Shinkawa T; Ohuchida K; Mochida Y; Sakihama K; Iwamoto C; Abe T; Ideno N; Mizuuchi Y; Shindo K; Ikenaga N; Moriyama T; Nakata K; Oda Y; Nakamura M
    J Exp Clin Cancer Res; 2022 Mar; 41(1):89. PubMed ID: 35272688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vimentin Expression in Tumor Microenvironment Predicts Survival in Pancreatic Ductal Adenocarcinoma: Heterogeneity in Fibroblast Population.
    Maehira H; Miyake T; Iida H; Tokuda A; Mori H; Yasukawa D; Mukaisho KI; Shimizu T; Tani M
    Ann Surg Oncol; 2019 Dec; 26(13):4791-4804. PubMed ID: 31583548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. circCUL2 induces an inflammatory CAF phenotype in pancreatic ductal adenocarcinoma via the activation of the MyD88-dependent NF-κB signaling pathway.
    Zheng S; Hu C; Lin H; Li G; Xia R; Zhang X; Su D; Li Z; Zhou Q; Chen R
    J Exp Clin Cancer Res; 2022 Feb; 41(1):71. PubMed ID: 35189958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inter- and intra-tumoural heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma.
    Neuzillet C; Tijeras-Raballand A; Ragulan C; Cros J; Patil Y; Martinet M; Erkan M; Kleeff J; Wilson J; Apte M; Tosolini M; Wilson AS; Delvecchio FR; Bousquet C; Paradis V; Hammel P; Sadanandam A; Kocher HM
    J Pathol; 2019 May; 248(1):51-65. PubMed ID: 30575030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-cell RNA-seq reveals dynamic change in tumor microenvironment during pancreatic ductal adenocarcinoma malignant progression.
    Chen K; Wang Q; Li M; Guo H; Liu W; Wang F; Tian X; Yang Y
    EBioMedicine; 2021 Apr; 66():103315. PubMed ID: 33819739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mesenchymal Plasticity Regulated by Prrx1 Drives Aggressive Pancreatic Cancer Biology.
    Feldmann K; Maurer C; Peschke K; Teller S; Schuck K; Steiger K; Engleitner T; Öllinger R; Nomura A; Wirges N; Papargyriou A; Jahan Sarker RS; Ranjan RA; Dantes Z; Weichert W; Rustgi AK; Schmid RM; Rad R; Schneider G; Saur D; Reichert M
    Gastroenterology; 2021 Jan; 160(1):346-361.e24. PubMed ID: 33007300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Schwann cells regulate tumor cells and cancer-associated fibroblasts in the pancreatic ductal adenocarcinoma microenvironment.
    Xue M; Zhu Y; Jiang Y; Han L; Shi M; Su R; Wang L; Xiong C; Wang C; Wang T; Deng S; Wu D; Cao Y; Dong L; Bai F; Zhao S; Deng X; Peng C; Li H; Chen J; Shen B; Jiang L; Chen H
    Nat Commun; 2023 Jul; 14(1):4600. PubMed ID: 37524695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opportunities and delusions regarding drug delivery targeting pancreatic cancer-associated fibroblasts.
    Liu H; Shi Y; Qian F
    Adv Drug Deliv Rev; 2021 May; 172():37-51. PubMed ID: 33705881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes.
    Zhao L; Zhao H; Yan H
    BMC Cancer; 2018 May; 18(1):603. PubMed ID: 29843660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer-associated fibroblasts reprogram cysteine metabolism to increase tumor resistance to ferroptosis in pancreatic cancer.
    Zhu Y; Fang S; Fan B; Xu K; Xu L; Wang L; Zhu L; Chen C; Wu R; Ni J; Wang J
    Theranostics; 2024; 14(4):1683-1700. PubMed ID: 38389839
    [No Abstract]   [Full Text] [Related]  

  • 11. Glypican-1 Is a Novel Target for Stroma and Tumor Cell Dual-Targeting Antibody-Drug Conjugates in Pancreatic Cancer.
    Tsujii S; Serada S; Fujimoto M; Uemura S; Namikawa T; Nomura T; Murakami I; Hanazaki K; Naka T
    Mol Cancer Ther; 2021 Dec; 20(12):2495-2505. PubMed ID: 34583978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unique metabolic features of pancreatic cancer stroma: relevance to the tumor compartment, prognosis, and invasive potential.
    Knudsen ES; Balaji U; Freinkman E; McCue P; Witkiewicz AK
    Oncotarget; 2016 Nov; 7(48):78396-78411. PubMed ID: 27623078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterogeneity of Cancer-Associated Fibroblasts and the Tumor Immune Microenvironment in Pancreatic Cancer.
    Shinkawa T; Ohuchida K; Nakamura M
    Cancers (Basel); 2022 Aug; 14(16):. PubMed ID: 36010986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient-specific modeling of stroma-mediated chemoresistance of pancreatic cancer using a three-dimensional organoid-fibroblast co-culture system.
    Schuth S; Le Blanc S; Krieger TG; Jabs J; Schenk M; Giese NA; Büchler MW; Eils R; Conrad C; Strobel O
    J Exp Clin Cancer Res; 2022 Oct; 41(1):312. PubMed ID: 36273171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL1-Induced JAK/STAT Signaling Is Antagonized by TGFβ to Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma.
    Biffi G; Oni TE; Spielman B; Hao Y; Elyada E; Park Y; Preall J; Tuveson DA
    Cancer Discov; 2019 Feb; 9(2):282-301. PubMed ID: 30366930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meflin-Positive Cancer-Associated Fibroblasts Inhibit Pancreatic Carcinogenesis.
    Mizutani Y; Kobayashi H; Iida T; Asai N; Masamune A; Hara A; Esaki N; Ushida K; Mii S; Shiraki Y; Ando K; Weng L; Ishihara S; Ponik SM; Conklin MW; Haga H; Nagasaka A; Miyata T; Matsuyama M; Kobayashi T; Fujii T; Yamada S; Yamaguchi J; Wang T; Woods SL; Worthley D; Shimamura T; Fujishiro M; Hirooka Y; Enomoto A; Takahashi M
    Cancer Res; 2019 Oct; 79(20):5367-5381. PubMed ID: 31439548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative characterization of stroma cells and ductal epithelium in chronic pancreatitis and pancreatic ductal adenocarcinoma.
    Helm O; Mennrich R; Petrick D; Goebel L; Freitag-Wolf S; Röder C; Kalthoff H; Röcken C; Sipos B; Kabelitz D; Schäfer H; Oberg HH; Wesch D; Sebens S
    PLoS One; 2014; 9(5):e94357. PubMed ID: 24797069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Aggressive Fibroblasts to Enhance the Treatment of Pancreatic Cancer.
    Yu Y; Schuck K; Friess H; Kong B
    Expert Opin Ther Targets; 2021 Jan; 25(1):5-13. PubMed ID: 33246383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer.
    Grossman JE; Muthuswamy L; Huang L; Akshinthala D; Perea S; Gonzalez RS; Tsai LL; Cohen J; Bockorny B; Bullock AJ; Schlechter B; Peters MLB; Conahan C; Narasimhan S; Lim C; Davis RB; Besaw R; Sawhney MS; Pleskow D; Berzin TM; Smith M; Kent TS; Callery M; Muthuswamy SK; Hidalgo M
    Clin Cancer Res; 2022 Feb; 28(4):708-718. PubMed ID: 34789479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decoding Metabolic Symbiosis between Pancreatic Cancer Cells and Cancer-Associated Fibroblasts Using Cultured Tumor Microenvironment.
    Nihashi Y; Song X; Yamamoto M; Setoyama D; Kida YS
    Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.